Terguride in stable Parkinson's disease.

Abstract

Terguride (TER) (2 mg/day) was compared with a placebo in 41 stable Parkinson's disease (PD) patients, so as to test its efficacy as an add-on treatment to spare levodopa (LD). After the 4th week of add-on treatment, LD was reduced by about 25%. The number of "stable" patients (--those with an increase of no more than 20% of the basal Columbia University Rating Scale (CURS) score--remaining after LD reduction was used to compare the two add-on treatments. Most patients, remained "stable" in spite of LD reduction, and no significant differences between the therapies were discovered; the CURS score decreased over time only in the TER group. Hence, TER was shown to be a drug that has DA-ergic properties but with minimal antiparkinsonian efficacy.

• Authors: E Martignoni, C Pacchetti, B Aufdembrinke, L Godi, G Albani, F Mancini, G Nappi
• Journal: Functional neurology (Funct Neurol) 1995 May-Jun Vol. 10 Issue 3 Pg. 143-6 ISSN: 0393-5264 [Print] Italy
• PMID: 8557216 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Dopamine Agonists
• Placebos
• dironyl
• Levodopa
• Lisuride

Topics

• Aged
• Dopamine Agonists (administration & dosage, therapeutic use)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Humans
• Levodopa (metabolism, therapeutic use)
• Lisuride (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
• Male
• Middle Aged
• Parkinson Disease (drug therapy)
• Placebos